Determinants of Adverse Drug Reactions Due to Tuberculosis Therapy in African Countries: a Systematic Scoping Review Protocol
Abstract Background: Adverse drug reactions (ADRs) remain a significant public health concern worldwide mainly in developing countries. Adverse drug reactions due to multi-drugs regimen for the treatment of tuberculosis (TB) have negative implications such as toxicity, leading to poor compliance and interruption of medication before completion. Understanding the profile of ADRs is critical to establishing specific strategies for early detection, prevention and clinical management. The present study aims to map the existing literature on the determinants of adverse drug reactions due tuberculosis therapy in African countries. Methods and analysis: The scoping review will be guided by Arksey and O’Malley framework as well as recommendations by Levac et al., and Colquhoun et al. The search strategy will include searching electronic databases such as Cochrane library, PubMed, EBSCOhost (including Medline), ProQuest, Google scholar; CINAHL with Full Text and other sources such as World Health Organization (WHO) and governmental websites. Peer-reviewed literature and grey literature of primary and secondary studies with different study designs which addresses the main question will be included. Studies published within the period of 2000 to 2020 are eligible. The selection process will involve screening titles, abstracts, full texts. A standardized data charting form will be created in google forms to extract relevant information from the included studies. The NVIVO software version 12 will be used for thematic analysis of the studies to summarize the review findings. The quality of the included studies will be assessed using Mixed Method Appraisal Tool (MMAT) version 2018 and Authority Accuracy Coverage Objectivity Date Significance (AACODS) checklist (for grey literatures).Discussion: The study anticipates finding and mapping relevant research studies in African context on determinants of adverse drug reactions due to tuberculosis therapy. The synthesis of this evidence base will help to identify research gaps and will serve as guidance for future research studies on strengthening of the pharmacovigilance system of ADRs and its clinical management in Africa. The study findings will be disseminated through the traditional academic platforms, such as peer-reviewed publications and presentations at relevant local and international conferences, symposiums, and seminars.Systematic review registration: Prospero Registration Number: CRD42020203617.